

Targeted consultation on options for a strategic approach to pharmaceuticals in the environment

Fields marked with * are mandatory.

1. About this consultation

This targeted consultation, aimed at stakeholders with specific relevant expertise, complements an open public consultation taking place as part of a study aimed at supporting the development of a European Union (EU) strategic approach to pharmaceuticals in the environment, and in turn at helping the EU achieve the United Nations Sustainable Development Goals, in particular SDG 6 ("Clean Water and Sanitation"), as well as objectives in EU legislation such as the "good status" objective in the Water Framework Directive. Adoption of the approach is to be followed by proposals for specific measures, as appropriate, which would be subject to full impact assessment. Experts are free to respond to both questionnaires, but are requested not to submit the same additional information twice over.

Pharmaceuticals can enter the environment during their production, use and disposal. The need for a strategic approach has been prompted by concern about risks to the environment itself, and possibly to human health via the environment. Any actions to address those risks must also ensure that humans and animals can continue to benefit from the appropriate use of pharmaceuticals and that the competitiveness of EU healthcare systems is maintained.

This targeted consultation aims to collect feedback and further information from stakeholders on 30 possible policy options identified on the basis of a review of the recent literature and preliminary consultation of stakeholders.

A background paper, provided with this questionnaire, describes the options. We advise you to read the paper or the summary of it before answering the questions. The full titles of the 30 policy options are presented in the introduction to the background document under the 10 action areas presented in that document and its summary. The full titles are also listed in this questionnaire but used in shortened form in the individual questions. In section 5.1, questions are posed in relation to effectiveness and timescale, Sections 5.2 and 5.3 ask about the costs and ease of implementing each option. Section 6 allows you to propose additional options.

Your responses will help the European Commission (EC) to identify and to narrow down options for further consideration. Thank you in advance.

2. Important note on the publication of answers

Please note that the responses received will be published on the EC's website, together with the identity of the contributor unless the contributor objects to the publication of personal data.

*** 1. Please indicate your preference as regards publication of your contribution**

- My contribution may be published, mentioning my name or the name of my organisation as well as country of residence
- My contribution may be published anonymously

Please note that, whatever option chosen, your answers may be subject to a request for public access to documents under [Regulation \(EC\) N°1049/2001](#). Please also read the specific privacy statement attached.

3. About the respondent

*** 2. Are you replying as:**

- An individual
- An EU institution
- A national/regional/local public authority
- A company
- A business or workers' organisation
- An NGO, environmental or consumer group
- A research organisation
- Other

*** 3a. Please state your name or the name of your organisation (published)**

EurEau - European Federation of National Associations of Water Services

*** 3b. Please provide an email address.** *Please note that your email address will not be published, even if you accepted that your name and country are published.*

carla.chiaretti@eureau.org

*** 5. How many members does your organisation or group represent?**

32 national organisation of water services from 29 European countries

*** 6. Is your organisation registered in the Transparency Register of the European Commission?**

- Yes
- No

*** 7. Please enter the identification number**

39299129772-62

*** 8. What is your main field of activity or main area of expertise or interest?**

- Pharmaceuticals
- Human healthcare (including pharmacy)
- Veterinary care (including veterinary pharmacy)
- Water and waste water management
- Waste management
- Other

*** 9. What is your main country of residence or activities? (published)**

- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovak Republic
- Slovenia
- Spain
- Sweden
- United Kingdom
- Other

*** If other, please specify (published)**

EU, Switzerland, Norway and Serbia

4. Numbered list of options - full titles

The full titles of the 30 policy options are presented below under the 10 action areas presented in the background document (and summary). In section 5.1, questions are posed in relation to effectiveness and timescale, Sections 5.2 and 5.3 ask about the costs and ease of implementing each option. Section 6 allows you to propose additional options. Please refer to the full title of each option when answering the questions.

Whole life-cycle - knowledge base: options for improving the understanding of risks from pharmaceuticals to the environment.

1 Provide further EU funding for, and encourage Member States and industry to fund, research regarding the fate, behaviour and impacts of pharmaceuticals in the environment

2 Provide EU funding for, and encourage Member States and industry to fund, research on the role of antimicrobials/resistant microorganisms in the environment on the emergence and spread of antimicrobial resistance (AMR) and its link with human and animal health

Design: option for designing greener substances.

3 Develop information resources and EU/industry co-funding initiatives to promote the design of active pharmaceutical ingredients (APIs) that pose lower risks to the environment.

Authorisation: options for ensuring the scientific robustness, consistency and transparency of risk assessments:

4 Strengthen the environmental expertise of the European Medicines Agency (EMA, its scientific committees) and the national competent authorities.

5 Ensure that all environmentally relevant toxicological thresholds for pharmaceuticals placed on the market are systematically made publicly available in a standardised format

6 Develop a system for sharing comprehensive active-substance-based Environmental Risk Assessments (ERAs) at EU level

7 Ensure that ERA results are systematically considered in the overall benefit/risk analysis for the authorisation of HMPs

8 Ensure that ERAs adequately consider Persistent Bio-accumulative and Toxic substances (PBT) and endocrine properties for the APIs, as well as the toxicity and other properties of major metabolites, degradation products and excipients: a) for human pharmaceuticals, b) for veterinary pharmaceuticals.

Manufacturing: options for promoting greener manufacturing processes:

9 Under the Industrial Emissions Directive, review and revise Best Available Techniques Reference (BREF) documents relevant to emissions from the manufacturing of pharmaceuticals

10 Prepare a sectoral reference document under the European Eco-Management and Audit Scheme (EMAS) to promote increased adoption by pharmaceutical companies, and by their global suppliers, of good environmental manufacturing standards

11 Ensure that EU Good Manufacturing Practices (GMP) address discharges of active pharmaceutical ingredients (APIs), degradation products and excipients into the environment

Post-authorisation: options for ensuring environmental risks are adequately taken into account and dealt with by mitigation actions where relevant

12 Instigate an Environmental Risk Assessment (ERA) catching-up procedure for relevant pharmaceuticals for which there is still no or only an incomplete ERA

13 Require from the marketing authorisation holder (MAH) the update/revision of ERAs based on post-marketing monitoring data or newly published information

14 Link the need for a prescription to supply/obtain human pharmaceuticals (HMPs) to the results of ERAs, and provide guidelines for the enforcement of existing similar provisions for veterinary pharmaceuticals (VMPs)

15 Require Member States to designate the authority/authorities responsible at national level for the follow-up and reporting obligations linked to implementation of risk mitigation measures

Use: options for:

- Ensuring environmental risks and impacts observed post-marketing are identified and reported

16 Establish routine dialogue and information exchange between relevant Member State agencies and authorities to help ensure that API levels in the environment are safe for the environment and human and animal health

17 Ensure that environmental issues are a) introduced into the pharmacovigilance system for human pharmaceuticals (HMPs) and b) strengthened for veterinary pharmaceuticals (VMPs), particularly in relation to AMR

18 Include pharmaceuticals as relevant in the watch lists for monitoring surface and groundwater under the Water Framework Directive (WFD) a) along with AMR in relevant microorganisms when antimicrobials are included; b) without requiring monitoring of AMR

- Promoting sustainable use of pharmaceuticals

19 Encourage Member States to increase the consideration of environmental aspects during medical /veterinary education and advanced training of healthcare professionals including healthcare managers

20 Ensure the provision of information to the general public that encourages the sustainable use of pharmaceuticals, in particular antimicrobials

21 Develop recommendations or requirements regarding the size and form of packaging for pharmaceuticals to facilitate their efficient use

Waste collection and disposal: options for ensuring appropriate collection and disposal of unused pharmaceuticals and pharmaceutical waste:

22 Promote better enforcement of EU legislation with regard to the implementation of waste collection schemes for human and veterinary pharmaceuticals, including through extended producer responsibility

23 Ensure that the CLP Regulation does not exclude pharmaceuticals in medicinal products, and that its provisions are consistent with the Waste Framework Directive

Waste treatment and reuse: options for promoting more effective treatment of waste water, manure and sludge.

24 Establish EU guidelines for appropriate wastewater management in hospitals and healthcare centres

25 Require monitoring of antimicrobials and AMR microorganisms in the effluent and organic waste from potential "hotspots" such as large waste water treatment plants, hospitals, pharmaceutical manufacturing sites and intensive livestock farms

26 Develop EU funding opportunities for research, development and implementation of advanced water treatment technologies to ensure that levels of pharmaceuticals, including antibiotics, and of AMR microorganisms, are reduced

27 Encourage Member States to establish innovative mechanisms for investing in advanced (waste and drinking) water treatment

28 Take additional measures, e.g. set quality standards or risk assessment requirements, to ensure that the concentrations of relevant pharmaceuticals and AMR microorganisms in manure, sewage sludge, and irrigation water are safe before it can be spread on agricultural fields

29 Encourage Member States to revise their Codes of Good Agricultural Practice and revise relevant best available techniques under the IED at EU level to include provisions for the handling of manure containing pharmaceuticals/AMR microorganisms

Whole life-cycle – overall management: option for promoting better overall management of pharmaceutical emissions into soils and the aquatic environment

5. Detailed questions on possible options

5.1 Effectiveness of options

10. How effective do you think the options listed above (in section 4) and in the background document would be in terms of mitigating risks from pharmaceuticals in the environment, in particular by way of reducing the presence of pharmaceuticals in the environment that could have harmful effects on or via the environment?

	Very effective	Moderately effective	Slightly effective	Not effective	Don't know
1 Research on pharmaceuticals in the environment	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
2 Research on pharmaceuticals and AMR	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
3 Promote greener pharmaceuticals design	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
4 Strengthen environmental expertise of EMA and national authorities	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
5 Toxicological thresholds for pharmaceuticals publicly available in standardised format	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
6 System for sharing substance-based ERAs at EU level	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
7 Benefit/risk analysis of ERA results in HMP authorisation	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
8a ERA adequately considers PBT, endocrine properties, metabolites, degradation products and excipients: HMPs	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
8b ERA adequately considers PBT, endocrine properties, metabolites, degradation products and excipients: VMPs	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
9 Review and revise BREF documents	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
10 Prepare EMAS ref. document	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

11 Ensure GMP addresses discharges	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
12 ERA catching up procedure	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
13 Update/revision of ERAs	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
14 Link need for prescription to supply HMPs to the results of ERAs	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
15 National authorities for follow-up and reporting obligations	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
16 Routine dialogue and information exchange on API levels	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
17a Introduce environmental issues in pharmacovigilance for HMPs	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
17b Strengthen environmental issues in pharmacovigilance for VMPs	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
18a Relevant pharmaceuticals in WFD watch lists: with AMR microorganisms	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
18b Relevant pharmaceuticals in WFD watch lists: without AMR	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
19 Increased consideration of environmental aspects in education and training	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
20 Information to encourage sustainable use of pharmaceuticals	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
21 Packaging pharmaceuticals for efficient use	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
22 Enforcement of waste collection schemes, including through EPR	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
23 CLP includes pharmaceuticals in products, in line with Waste FD	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
24 EU guidelines on waste water from hospitals	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
25 Monitoring of antimicrobials and AMR microorganisms at discharge "hotspots"	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
26 EU funding for advanced water treatment technologies	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
27 Innovative MS mechanisms for investment in advanced water treatment	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

28 Safe concentrations of pharmaceuticals and AMR microorganisms in waste(water) for agricultural use	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
29 Revised Codes of Good Agricultural Practice and BAT under IED	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
30 Guidance under CIS for WFD	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

11. If you considered an option as slightly, moderately or very effective, over what timescale(s) would you see it having an effect? (Please select all timescales that apply if, e.g. there is more than one effect.)

	Soon, i.e. within 6 months	More than 6 months away, but less than 2 years	After 2 years or more
1 Research on pharmaceuticals in the environment	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
2 Research on pharmaceuticals and AMR	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
3 Promote greener pharmaceuticals design	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
4 Strengthen environmental expertise of EMA and national authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
5 Toxicological thresholds for pharmaceuticals publicly available in standardised format	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
6 System for sharing substance-based ERAs at EU level	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
7 Benefit/risk analysis of ERA results in HMP authorisation	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
8a ERA adequately considers PBT, endocrine properties, metabolites, degradation products and excipients: HMPs	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
8b ERA adequately considers PBT, endocrine properties, metabolites, degradation products and excipients: VMPs	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
9 Review and revise BREF documents	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
10 Prepare EMAS ref. document	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
11 Ensure GMP addresses discharges	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
12 ERA catching up procedure	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
13 Update/revision of ERAs	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>

14 Link need for prescription to supply HMPs to the results of ERAs	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
15 National authorities for follow-up and reporting obligations	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
16 Routine dialogue and information exchange on API levels	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
17a Introduce environmental issues in pharmacovigilance for HMPs	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
17b Strengthen environmental issues in pharmacovigilance for VMPs	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
18a Relevant pharmaceuticals in WFD watch lists: with AMR microorganisms	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
18b Relevant pharmaceuticals in WFD watch lists: without AMR	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
19 Increased consideration of environmental aspects in education and training	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
20 Information to encourage sustainable use of pharmaceuticals	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
21 Packaging pharmaceuticals for efficient use	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
22 Enforcement of waste collection schemes, including through EPR	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
23 CLP includes pharmaceuticals in products, in line with Waste FD	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
24 EU guidelines on waste water from hospitals	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
25 Monitoring of antimicrobials and AMR microorganisms at discharge “hotspots”	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
26 EU funding for advanced water treatment technologies	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
27 Innovative MS mechanisms for investment in advanced water treatment	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
28 Safe concentrations of pharmaceuticals and AMR microorganisms in waste(water) for agricultural use	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>
29 Revised Codes of Good Agricultural Practice and BAT under IED	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
30 Guidance under CIS for WFD	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

12. Please provide a brief explanation for your answers on the options, including any proposals for modifying them. Please also explain why you selected certain timescales. When responding, please indicate the number of the option you refer to.

1500 character(s) maximum

All measures involving changes of practices should be straightforward and their effects should be visible in the very short term. Legislative changes will of course produce their effects in a medium-long term. Measures entailing huge investments in projects will have impacts in the long term. Since many pharmaceuticals are not entirely biodegradable, once present in the water cycle, they can gradually accumulate and could pose a risk to drinking water resources and aquatic ecosystems. Technologies currently used in waste water treatment plants are not designed to remove pharmaceuticals and their metabolites. Existing advanced treatment processes rarely come out well in cost effectiveness and environmental performances analysis. Innovative technologies, but also other solutions, are needed to address these drawbacks: a study on the funding options according to the Extended Producer Responsibility is very welcome in this perspective. EurEau recognises that these initiatives may prove useful for tackling specific pharmaceuticals or addressing specific local conditions in the long term. The most sustainable and preferred solution however is to prevent pharmaceuticals from entering the water cycle and tackle along the different steps that precede their emission into the aquatic environment. As for waste, EPR would put in place clear targets via a sound legal framework and industry would be free to choose the most effective tools to achieve them: eco-design, substitutes..etc

5.2 Costs of implementing options

13. What do you consider the costs of implementing these options would be? Please consider only the direct costs to relevant stakeholder(s) who have to take the relevant measure(s), not "knock-on" costs to other stakeholders that might follow implementation. Please consider the costs in relation to the likely overall budget of the stakeholder; the last line allows you to consider the costs to all stakeholders instead of by stakeholder group (or in addition). The term "Public authorities" includes regulators and public healthcare providers.

1 Research on pharmaceuticals in the environment

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

2 Research on pharmaceuticals and AMR

	High costs	Moderate costs	Low costs	No costs	Don't know

Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

3 Promote greener pharmaceuticals design

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

4 Strengthen environmental expertise of EMA and national authorities

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

5 Toxicological thresholds for pharmaceuticals publicly available in standardised format

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

6 System for sharing substance-based ERAs at EU level

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

7 Benefit/risk analysis of ERA results in HMP authorisation

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

8a ERA adequately considers PBT, endocrine properties, metabolites, degradation products and excipients: HMPs

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
------------------	-----------------------	-----------------------	----------------------------------	-----------------------	-----------------------

8b ERA adequately considers PBT, endocrine properties, metabolites, degradation products and excipients: VMPs

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

9 Review and revise BREF documents

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

10 Prepare EMAS ref. document

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

11 Ensure GMP addresses discharges

--	--	--	--	--	--

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

12 ERA catching up procedure

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

13 Update/revision of ERAs

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

14 Link need for prescription to supply HMPs to the results of ERAs

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

15 National authorities for follow-up and reporting obligations

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

16 Routine dialogue and information exchange on API levels

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

17a Introduce environmental issues in pharmacovigilance for HMPs

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

17b Strengthen environmental issues in pharmacovigilance for VMPs

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

18a Relevant pharmaceuticals in WFD watch lists: with AMR microorganisms

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

18b Relevant pharmaceuticals in WFD watch lists: without AMR

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

19 Increased consideration of environmental aspects in education and training

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

20 Information to encourage sustainable use of pharmaceuticals

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

21 Packaging pharmaceuticals for efficient use

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

22 Enforcement of waste collection schemes, including through EPR

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

23 CLP includes pharmaceuticals in products, in line with Waste FD

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

24 EU guidelines on waste water from hospitals

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

25 Monitoring of antimicrobials and AMR microorganisms at discharge “hotspots”

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

26 EU funding for advanced water treatment technologies

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Individual citizens	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

27 Innovative MS mechanisms for investment in advanced water treatment

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

28 Safe concentrations of pharmaceuticals and AMR microorganisms in waste(water) for agricultural use

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
------------------	-----------------------	-----------------------	-----------------------	----------------------------------	-----------------------

29 Revised Codes of Good Agricultural Practice and BAT under IED

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

30 Guidance under CIS for WFD

	High costs	Moderate costs	Low costs	No costs	Don't know
Public authorities	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Pharmaceutical and healthcare industry	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Water and waste treatment industries	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Individual citizens	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
All stakeholders	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>

14. Please provide a brief explanation for your answers on the costs of the options. Please also specify how you think costs should be distributed among stakeholders. When responding, please indicate the number of the option you refer to.

1500 character(s) maximum

The costs have been estimated making a comparison between the various options. The polluter pays principle should be applied when calculating and allocating the costs. For this reason EurEau supports the European Commission idea to evaluate the application of the Extended Producers Responsibility also to pharmaceuticals products as it has been applied already in other environmental legislation (waste legislation such as the WEEE Directive). It is undeniable that the inclusion of EPR in the waste legislation has led to improvement in the protection of the environment from waste, so the same thing is possible for the protection of water resources. The EPR should be applied through a sound legislative framework by which targets are set: it is then up to the pharmaceutical industry (the producers) to decide how to reach them. The producers will be free to choose the most effective tools such as eco-design measures, alternative products/substitutes or financing end-of-life measures. This will create an incentive for the producers to change the current practices and embrace the responsibility across the life-cycle of their products.

5.3 Ease of implementing options

15. How easily do you think these options could be implemented? Please consider the relevant aspects of feasibility; leave blank any aspect you consider not relevant. Capacity-related is intended to cover resource availability and logistical aspects.

1 Research on pharmaceuticals in the environment

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

2 Research on pharmaceuticals and AMR

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

3 Promote greener pharmaceuticals design

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

4 Strengthen environmental expertise of EMA and national authorities

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

5 Toxicological thresholds for pharmaceuticals publicly available in standardised format

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

6 System for sharing substance-based ERAs at EU level

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

7 Benefit/risk analysis of ERA results in HMP authorisation

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

8a ERA adequately considers PBT, endocrine properties, metabolites, degradation products and excipients: HMPs

	Very easily	Moderately easily	Not easily	Don't know

Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

8b ERA adequately considers PBT, endocrine properties, metabolites, degradation products and excipients: VMPs

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

9 Review and revise BREF documents

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

10 Prepare EMAS ref. document

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

11 Ensure GMP addresses discharges

--	--	--	--	--

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

12 ERA catching up procedure

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

13 Update/revision of ERAs

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

14 Link need for prescription to supply HMPs to the results of ERAs

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

15 National authorities for follow-up and reporting obligations

--	--	--	--	--

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

16 Routine dialogue and information exchange on API levels

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

17a Introduce environmental issues in pharmacovigilance for HMPs

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

17b Strengthen environmental issues in pharmacovigilance for VMPs

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

18a Relevant pharmaceuticals in WFD watch lists: with AMR microorganisms

	Very easily	Moderately easily	Not easily	Don't know
	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

18b Relevant pharmaceuticals in WFD watch lists: without AMR

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

19 Increased consideration of environmental aspects in education and training

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

20 Information to encourage sustainable use of pharmaceuticals

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

21 Packaging pharmaceuticals for efficient use

	Very easily	Moderately easily	Not easily	Don't know
	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

22 Enforcement of waste collection schemes, including through EPR

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

23 CLP includes pharmaceuticals in products, in line with Waste FD

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

24 EU guidelines on waste water from hospitals

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

25 Monitoring of antimicrobials and AMR microorganisms at discharge “hotspots”

	Very easily	Moderately easily	Not easily	Don't know
	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

26 EU funding for advanced water treatment technologies

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Social acceptability	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>

27 Innovative MS mechanisms for investment in advanced water treatment

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

28 Safe concentrations of pharmaceuticals and AMR microorganisms in waste(water) for agricultural use

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

29 Revised Codes of Good Agricultural Practice and BAT under IED

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

30 Guidance under CIS for WFD

	Very easily	Moderately easily	Not easily	Don't know
Legal	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Technical	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Capacity-related	<input type="radio"/>	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>
Social acceptability	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

16. Please provide a brief explanation for your answers on the implementation of the options. When responding, please indicate the number of the option you refer to.

1500 character(s) maximum

Pharmaceutical products play an important role in our societies' health and wellbeing, but we know very little on the environmental impact since ERAs are not available (only summaries are available). EurEau agrees to speed up the catching up on ERAs and also would welcome an extended post-authorisation ERA (option 12 and 13). If social acceptability of the ERA (option 14) being part of the cost-benefit analysis can be difficult, it should be stressed that social acceptability is also very difficult for consumers of drinking water that do not want traces of pharmaceuticals in their tap water nor in the water resources.

6. Further information

If you are responding to both this and the open public consultation, please do not provide the same additional information twice over.

17. What aspect of the issue (of pharmaceuticals in the environment) concerns you most?

500 character(s) maximum

The growing presence of pharmaceuticals in water resources and the lack of a coherent strategy to address this, is what concerns EurEau the most. In 2013 when the Priority Substances Directive was negotiated it seemed that extra treatment at the end of the pipe was the only option. Now we see that there are many levels – at least 30 options - to act on and actors to be involved. The Strategy should better take into account options concerning the input of veterinary pharmaceuticals.

18. If you are aware of any options already being implemented in your own country, please mention them and provide details.

1500 character(s) maximum

In the Netherlands and in Germany strategies have been developed and measures are taken across the whole life cycle of the pharmaceuticals and at all levels. Particularly useful is the engagement with health care professionals. The Swiss approach to micropollutants should also be studied in its entirety, taking into account the cost-effectiveness of the measures, the removal rates and the impacts on the aquatic environment.

19. Please feel free to suggest further options, in addition to those included in this questionnaire or mentioned in your answer to Q.18, to address the impacts of pharmaceuticals in the environment. Please indicate the phase of the lifecycle of the option(s) and likely effectiveness, costs and degree of feasibility.

1500 character(s) maximum

More emphasis on the veterinary pharmaceuticals in the environment is needed, especially since there are no prescription practices in place. The take-back schemes at national levels should also be implemented everywhere. Consumers should be better informed both on the PiE topic and the possibilities to dispose of pharmaceuticals in a correct way: for this European Consumers associations are an important stakeholder in the definition of the strategic approach. If water and soil are considered, there are no options considering the possible impact of the emissions from the incineration of pharmaceuticals on the atmosphere.

20. We invite you to suggest information sources on pharmaceuticals and the environment (titles of publications and web links are appreciated) in order to increase the evidence base on the topics addressed in this questionnaire.

1500 character(s) maximum

ECODRUG website: <http://www.ecodrug.org/>

EurEau position papers on:

- Source Control for micropollutants (2016): http://eureau.org/administrator/components/com_europublication/pdf/63ffd2b6432094f92ff50cea0d0c293e-20160527-EurEau-Position-Paper-Source-Control-for-Micropollutants-final.pdf

- Strategy on veterinary pharmaceuticals (2015): http://eureau.org/administrator/components/com_europublication/pdf/0397505525d7954b4f472b7ac24d268e-EurEau---s-Contribution-to-the-European-Commission---s-Strategic-Approach-on-Veterinary-Pharmaceuticals-in-the-Environment.pdf

- Strategy on PiE (2014): http://eureau.org/administrator/components/com_europublication/pdf/d127f8273bad53d568242fdc3a3c9f26-2014.05.26_PP_on_Pharmaceuticals.pdf

If you wish to submit additional documentation (up to three pages), please upload your file here.

The maximum file size is 1 MB

Background Documents

[Background_Paper.pdf \(/eusurvey/files/41a5e4c1-9091-4f11-adf1-e6b92bc1fe05\)](/eusurvey/files/41a5e4c1-9091-4f11-adf1-e6b92bc1fe05)

[Study report \(/eusurvey/files/472cd6f7-1c2b-470d-8b6f-582d3a6bcd0b\)](/eusurvey/files/472cd6f7-1c2b-470d-8b6f-582d3a6bcd0b)

[Summary_Background_Paper.pdf \(/eusurvey/files/f520d2e2-fd04-4651-a5d2-1600fe178f90\)](/eusurvey/files/f520d2e2-fd04-4651-a5d2-1600fe178f90)

Contact

ENV-PHARMA-CONSULTATION@ec.europa.eu
